Itoh, K <br/><br/>
Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Sep 2002 
 - 1347-55 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdf287  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Confidence Intervals<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Infusions, Intravenous<br/>Japan<br/>Lenograstim<br/>Lymphoma, Non-Hodgkin--diagnosis<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neutropenia--prevention & control<br/>Prednisolone--administration & dosage<br/>Probability<br/>Recombinant Proteins--administration & dosage<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--administration & dosage